Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (Note: Input metadata referenced "Sanara Medtech Inc.", but the filing text identifies the registrant as Wound Management Technologies, Inc.)
Reporting Period: Quarter ended March 31, 2009
Business Overview: The Company distributes FDA-cleared collagen-based wound care products (CellerateRx) to healthcare providers. Operations are currently limited, with manufacturing and warehousing outsourced. The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $53,428 | $63,270 |
| Cost of Sales | $310,145 | $148,236 |
| Gross Profit (Loss) | $(256,717) | $(84,966) |
| Net Loss | $(509,258) | $(353,233) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.02) |
| Cash and Equivalents (End of Period) | $104,539 | $406,327 |
| Total Current Liabilities | $1,045,353 | $472,971 |
| Stockholders' Deficiency | $(762,514) | $(321,257) |
Liquidity: Net cash used in operating activities was $423,673. The Company raised $527,070 in financing activities, primarily through short-term debt ($200,000) and related party notes ($327,070).
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased approximately 16% to $53,428 compared to $63,270 in the prior year quarter.
- Gross Margin Deterioration: The Company reported a gross loss of $256,717, a significant increase from the $84,966 gross loss in the prior year. Cost of sales ($310,145) exceeded revenue by a wide margin.
- Increased Debt Load: Current liabilities more than doubled from $472,971 to $1,045,353. This includes new notes payable of $205,833 (net of discount) and related party notes of $327,070, which were zero in the prior period.
- Accumulated Deficit: The accumulated deficit grew from $(14,772,577) to $(15,281,834).
Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that conditions raise "substantial doubt" about the Company's ability to continue as a going concern. The Company has continuously incurred losses and requires additional financing to meet obligations for the next 12 months. Management plans to raise capital via private placements, issuing stock for services, or loans from shareholders.
Delinquent Taxes: The Company is delinquent on federal payroll taxes. As of March 31, 2009, unpaid taxes totaled approximately $203,000, with estimated penalties and interest of $168,000 included in current liabilities.
Debt Obligations:
- A discounted note of $200,000 (face value $215,000) is due May 22, 2009, bearing 18% interest.
- Related party notes totaling $327,070 are due, some of which are currently in default.
Legal Proceedings: The Company is a defendant in a civil suit regarding stock transactions from 1997. Management intends to defend vigorously.
Guidance: No specific financial guidance was provided. Management anticipates continuing nominal losses for the next twelve months.
Investor Verification Checklist
- Capital Sufficiency: Verify if the Company has secured the additional debt or equity financing required to survive the next 12 months, given the "substantial doubt" disclosure.
- Tax Liability Resolution: Confirm the status of negotiations with the IRS regarding the $203,000 delinquent payroll tax liability and associated penalties.
- Debt Maturity: Assess the ability to repay the $200,000 high-interest note due May 22, 2009, and the $327,070 in related party notes.
- Revenue Viability: Evaluate the sustainability of the business model given that Cost of Sales ($310k) significantly exceeds Revenue ($53k) for the quarter.
- Legal Exposure: Monitor the outcome of the 1997 stock transaction lawsuit.